RecruitingPancreatic CancerPancreatic Cancer MetastaticPDAC
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.
Sponsor: Revolution Medicines, Inc.
You may qualify if…
- ✓ At least 18 years old and has provided informed consent.
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- ✓ Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally advanced unresectable or metastatic setting.
- ✓ No prior treatment in the locally advanced unresectable or metastatic setting
- ✓ Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.
- ✓ Documented KRAS G12D mutation status.
- ✓ Measurable disease per RECIST v1.1.
- ✓ Adequate organ function (bone marrow, liver, kidney, coagulation).
You may not qualify if…
- ✕ Mutation status with known driver mutations for which there are approved targeted therapies.
- ✕ Acinar cell carcinoma, pancreatic neuroendocrine tumors, tumors involving islet cells or islet cell neoplasms, and other non-adenocarcinoma pancreatic malignancies.
- ✕ Tumors determined to originate from non-pancreatic primary sites.
- ✕ Prior treatment with MAPK-pathway targeted therapy or administration of RAS-targeted vaccine in the metastatic setting.
- ✕ Active or known history of untreated central nervous system metastatic or leptomeningeal disease.
- ✕ Any conditions that may affect the ability to take or absorb study drug.
- ✕ Major surgery within 28 days prior to randomization.
- ✕ Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07805954 · last updated 2026-11-06